GT Biopharma Inc (GTBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 6,511 | 9,249 | 1,950 | 1,079 | 2,648 |
| Marketable Securities | N/A | N/A | 7,857 | 12,893 | 13,366 |
| TOTAL | $6,759 | $9,267 | $9,885 | $14,056 | $16,052 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 0 | 0 | 27 | 53 | 96 |
| TOTAL | $N/A | $N/A | $27 | $53 | $96 |
| Total Assets | $6,759 | $9,267 | $9,912 | $14,109 | $16,148 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,612 | 1,717 | 3,213 | 4,328 | 3,970 |
| Accrued Expenses | 1,868 | 1,765 | 963 | 1,195 | 1,028 |
| Other current liabilities | 182 | 277 | 394 | 1,052 | N/A |
| TOTAL | $4,662 | $3,759 | $4,600 | $6,633 | $5,090 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 1,053 |
| TOTAL | $N/A | $N/A | $N/A | $N/A | $1,053 |
| Total Liabilities | $4,662 | $3,759 | $4,600 | $6,633 | $6,143 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 2,234 | 2,234 | 1,417 | 1,381 | 1,379 |
| Common Shares | 2 | 2 | 1 | 1 | 42 |
| Retained earnings | -691,452 | -688,041 | -684,331 | -682,065 | -679,103 |
| Other shareholders' equity | 1 | 1 | 1 | 1 | 1 |
| TOTAL | $2,097 | $5,508 | $5,312 | $7,476 | $10,005 |
| Total Liabilities And Equity | $6,759 | $9,267 | $9,912 | $14,109 | $16,148 |